Nabriva Therapeutics (NASDAQ:NBRV) has been assigned a $13.00 target price by analysts at Northland Securities in a research report issued to clients and investors on Friday, TipRanks reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Northland Securities’ price target suggests a potential upside of 488.24% from the stock’s current price.
The analysts wrote, “We believe Xenleta is positioned to emerge as the 1st empiric monotherapy for treating CABP w/ potential global peak sales of $1B, supported by its significant clinical differentiation from existing therapies. Key Points Xenleta IV and Nabriva announced the FDA approval of Xenleta (lefamulin) IV and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) in adults. This represents the first approval of a new class antibiotic in nearly 2 decades. Xenleta is a semi-synthetic pleuromutilin that works via a unique mechanism of action by inhibiting the synthesis of bacteria protein necessary of proliferation.””
Several other analysts also recently issued reports on NBRV. Gabelli raised shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating and set a $2.00 price objective for the company in a research report on Thursday, May 2nd. ValuEngine raised shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub downgraded shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 24th. HC Wainwright set a $7.00 price objective on shares of Nabriva Therapeutics and gave the company a “buy” rating in a research report on Sunday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Nabriva Therapeutics in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $7.06.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.04. Nabriva Therapeutics had a negative net margin of 3,602.24% and a negative return on equity of 139.52%. The company had revenue of $0.53 million during the quarter, compared to the consensus estimate of $0.88 million. On average, equities analysts anticipate that Nabriva Therapeutics will post -1.1 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $29,000. Fosun International Ltd purchased a new position in shares of Nabriva Therapeutics during the 1st quarter valued at approximately $1,593,000. FMR LLC boosted its stake in shares of Nabriva Therapeutics by 514.2% during the 4th quarter. FMR LLC now owns 1,842,700 shares of the biotechnology company’s stock valued at $2,690,000 after buying an additional 1,542,700 shares during the last quarter. Two Sigma Advisers LP purchased a new position in shares of Nabriva Therapeutics during the 4th quarter valued at approximately $37,000. Finally, Morgan Stanley boosted its stake in shares of Nabriva Therapeutics by 52.9% during the 2nd quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock valued at $645,000 after buying an additional 91,869 shares during the last quarter. Institutional investors own 3.10% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Featured Article: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.